Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Described herein is a liquid enzyme preparation containing component (a): at least one salt according to general formula (I)
(R.sup.2).sub.3N.sup.+—(CH.sub.2).sub.nC(R.sup.3)(R.sup.4)—(O—X).sub.m—O—C(O)—R.sup.1A.sup.−  (I) wherein n is selected from 1 to 12, m is selected from zero to 50, R.sup.1 is selected from the group consisting of methyl, ethyl, —CH(OH)—CH(OH)—COOH, CH(OH)—CH.sub.3, (E)-CH═CHCOOH, (Z)—CH═CHCOOH, —C.sub.6H.sub.5, para-HO—C.sub.6H.sub.4—, o,p-dihydroxyphenyl, and 3,4,5-triydroxyphenyl, R.sup.2 are same or different and selected from C.sub.1-C.sub.10-alkyl, phenyl, R.sup.3 and R.sup.4 are same or different and selected from hydrogen and C.sub.1-C.sub.4-alkyl, X is C.sub.2-C.sub.4-alkylen, and A.sup.− is an inorganic or organic counteranion,
component (b): at least one enzyme selected from hydrolases (EC 3),
and
optionally component (c): at least one compound selected from enzyme stabilizers different from component (a), preservatives, and surfactants.

The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.

Provided in the present invention are a salt of an arylaminopurine derivative represented by Formula (2), a preparation method therefor and the use thereof. The salt obtained in the present invention has good crystallinity and significantly improved solubility relative to that in the free form, and the preferred salt and crystal form have low hygroscopicity and can exist stably. Therefore, compared with the free form of arylaminopurine derivatives or other salts, it is easier to prepare same into a medicine.

##STR00001##

The present invention relates to a new, enhanced process for the manufacture of Cysteamine Bitartrate (I) and of its key intermediate thiazolidine (II).

Furthermore, it relates to a new processes for the manufacture of crystalline anhydrous Cysteamine Bitartrate (polymorph L2) and monohydrate Cysteamine Bitartrate (polymorph L1). The crystalline anhydrous Cysteamine Bitartrate (polymorph L2) so obtained is characterized by particularly fine particle size and good appearance.